Pheochromocytoma: Diagnosis, Surgical Management and Long-Term Care — Cost, Top Hospitals & Success Rates | MyMedicPlus

Pheochromocytoma is a rare catecholamine-secreting neuroendocrine tumour arising from chromaffin cells of the adrenal medulla. Closely related tumours arising from extra-adrenal sympathetic (or parasympathetic) ganglia are termed paragangliomas. Together, phaeochromocytomas and paragangliomas (PPGLs) are classified under the broader PPGL umbrella in current endocrine oncology guidelines.

The historical "rule of 10s" — 10% bilateral, 10% extra-adrenal, 10% malignant, 10% familial — has been substantially revised by molecular genetics. Contemporary series indicate that approximately 35–40% of PPGLs are associated with germline mutations in one of 25+ susceptibility genes, making comprehensive genetic testing mandatory for all newly diagnosed patients.

Pheochromocytomas hypersecrete catecholamines (adrenaline/epinephrine, noradrenaline/norepinephrine, and to a lesser extent dopamine) and their O-methylated metabolites (metanephrine and normetanephrine). The characteristic clinical triad of episodic hypertension, headache, and diaphoresis (sweating) is pathognomonic when present, but many tumours present atypically or are discovered incidentally on abdominal imaging performed for other indications ("incidentaloma").

The annual incidence is approximately 2–8 per million population. Pheochromocytoma is identified in 0.1–0.6% of all hypertensive patients — a low absolute frequency but clinically critical because the condition is curable by surgery and potentially life-threatening if undiagnosed during procedures or childbirth. The Endocrine Society, European Society of Endocrinology, and ENSAT guidelines provide evidence-based frameworks for biochemical diagnosis, imaging, pre-operative preparation, and long-term follow-up. Adrenal medullary tumours are benign in approximately 90% of cases, though the WHO no longer uses the term "benign" — all PPGLs carry metastatic potential and are now classified as either localised or metastatic based on the presence of tumour in non-chromaffin tissue (lymph nodes, liver, bone, lung).

Pheochromocytoma presents across a wide clinical spectrum, from dramatic hypertensive emergencies to asymptomatic imaging incidentalomas:

• Classic paroxysmal presentation — Episodic catecholamine release produces the triad of severe headache, profuse sweating, and palpitations, typically lasting minutes to an hour. Paroxysms may be spontaneous or triggered by physical pressure on the abdomen, micturition (bladder paraganglioma), exercise, certain medications (glucagon, metoclopramide, histamine, tyramine-containing foods), or anaesthetic induction.
• Sustained hypertension — Some tumours cause persistent hypertension (especially predominantly norepinephrine-secreting tumours) rather than paroxysms, mimicking essential hypertension with resistance to standard antihypertensive therapy.
• Adrenal incidentaloma — Approximately 5–10% of adrenal incidentalomas (>1 cm adrenal mass found on imaging performed for unrelated reasons) are pheochromocytomas. All adrenal incidentalomas require biochemical evaluation including plasma fractionated metanephrines to exclude PPGL before any invasive procedure.
• Hereditary syndromes — Key associated syndromes include: Multiple Endocrine Neoplasia type 2 (MEN2A/B) — RET proto-oncogene mutation; PPGL occurs in 50% of MEN2A carriers. Von Hippel-Lindau (VHL) disease — VHL gene mutation; predominantly norepinephrine-secreting bilateral adrenal tumours. Neurofibromatosis type 1 (NF1) — NF1 mutation; PPGL in approximately 1–3%. SDH mutations (SDHA, SDHB, SDHC, SDHD) — Succinate dehydrogenase subunit mutations; highest malignancy risk with SDHB (approximately 40%).
• Metastatic paraganglioma — Defined by tumour in non-chromaffin tissue; occurs in approximately 10–15% of adrenal phaeochromocytomas and up to 40% of extra-adrenal paragangliomas. Bone, lymph nodes, liver, and lung are the commonest metastatic sites. SDHB mutation carriers have the highest metastatic risk.
• Phaeochromocytoma crisis — Life-threatening multi-organ failure caused by massive catecholamine surge, manifesting as hypertensive encephalopathy, pulmonary oedema, myocardial infarction, or cardiogenic shock. Requires emergency alpha-blockade and intensive care management.

Confirmed biochemical evidence of catecholamine excess is mandatory before any surgical or interventional procedure, including adrenal biopsy (which is absolutely contraindicated without prior biochemical exclusion of PPGL due to risk of hypertensive crisis from needle manipulation):

• Biochemical diagnosis — first-line tests: Plasma fractionated metanephrines (normetanephrine and metanephrine) — the preferred first-line test per Endocrine Society guidelines, with sensitivity of 97–99% and specificity of 82–96%. Blood is drawn after 30 minutes of supine rest to minimise sympathoadrenal activation. A result >3 times the upper limit of normal is essentially diagnostic. 24-hour urine fractionated metanephrines and catecholamines — an alternative first-line or confirmatory test with sensitivity 87–96% and specificity 86–98%.
• Interfering medications — Several medications falsely elevate metanephrine levels: tricyclic antidepressants, monoamine oxidase inhibitors, levodopa, methyldopa, labetalol (cross-reacts with catecholamine assays), and acetaminophen in some HPLC assays. These should be withdrawn for at least 2 weeks before testing where clinically feasible.
• Imaging localisation — Performed after biochemical confirmation. CT abdomen and pelvis with contrast (adrenal phase imaging) is the primary localisation modality. Sensitivity for adrenal tumours >2 cm exceeds 90%. MRI provides superior characterisation (T2 hyperintensity; absence of lipid on chemical shift), preferred in pregnancy, paediatric cases, and where CT reveals an indeterminate lesion. Functional imaging: 68Ga-DOTATATE PET/CT is the most sensitive functional imaging modality for PPGL, supplanting 123I-MIBG scintigraphy in most centres. 18F-FDG PET/CT is preferred for SDHB-associated metastatic disease.
• Genetic testing — Germline genetic panel (RET, VHL, SDHA/B/C/D, MAX, TMEM127, NF1, FH, MDH2) is recommended for all PPGL patients regardless of family history, young age, or sporadic presentation. Positive results trigger cascade testing of first-degree relatives.
• Pre-operative alpha-blockade — Mandatory before surgery. Phenoxybenzamine (non-selective, irreversible alpha-blocker) 10 mg twice daily, titrating to 20–30 mg twice daily over 10–14 days, is the gold standard. Doxazosin (selective alpha-1 blocker) 4–8 mg daily is a well-tolerated alternative. Beta-blockade (e.g., propranolol, atenolol) should ONLY be added after 10–14 days of adequate alpha-blockade to treat tachycardia — never given before alpha-blockade, as unopposed alpha-adrenergic vasoconstriction causes severe hypertension.

Surgical resection is the definitive treatment for localised pheochromocytoma. The treatment strategy is determined by tumour size, laterality, malignant potential, and hereditary syndrome:

• Laparoscopic adrenalectomy — The gold-standard surgical approach for unilateral adrenal phaeochromocytomas up to 8–10 cm. The transperitoneal lateral flank approach is most common. The posterior retroperitoneoscopic approach (PRA) is increasingly favoured at specialist centres as it avoids peritoneal entry, reduces handling of intraperitoneal organs, and may shorten operating time and recovery. Both approaches produce equivalent oncological outcomes. Patients are admitted for 1–3 days post-operatively.
• Open adrenalectomy — Reserved for tumours >10 cm, suspected local invasion, perioperative haemodynamic instability requiring direct vascular control, or tumours requiring en-bloc resection of adjacent structures. Midline laparotomy or subcostal incision provides the widest access and best vascular control.
• Cortical-sparing adrenalectomy — In patients with bilateral phaeochromocytoma (MEN2, VHL disease), partial adrenalectomy preserving the cortex avoids permanent Addisonian insufficiency and lifelong steroid dependence in approximately 80% of cases. Requires careful intraoperative judgement and carries a higher risk of local recurrence than total adrenalectomy.
• Intraoperative anaesthetic management — Specialised invasive monitoring (arterial line, central venous or pulmonary artery catheter) is required. Intraoperative hypertensive crises during tumour manipulation are controlled with intravenous phentolamine 2–5 mg boluses or sodium nitroprusside infusion. Post-resection hypotension responds to intravenous fluid loading; vasopressors are rarely needed if pre-operative alpha-blockade was adequate.
• 131I-MIBG therapy for metastatic disease — High-dose radioactive meta-iodobenzylguanidine (131I-MIBG, Azedra) is approved for MIBG-avid metastatic PPGL. Response rates: 22–25% complete or partial response by RECIST, 50–60% clinical benefit (symptom improvement and antihypertensive medication reduction).
• Peptide receptor radionuclide therapy (PRRT) — 177Lu-DOTATATE (Lutathera) is used for SSTR2-expressing metastatic paraganglioma in MIBG-negative or MIBG-refractory disease, with disease control rates of 50–70% based on DOTATATE PET avidity.
• Systemic targeted therapy — Sunitinib and cabozantinib (multi-kinase inhibitors) and temozolomide-based chemotherapy (CVD regimen) are used for refractory progressive metastatic disease.

Successful surgical treatment of pheochromocytoma delivers transformative benefits across multiple domains:

• Cure of hypertension — Approximately 70–80% of patients with pheochromocytoma-related hypertension achieve sustained blood pressure normalisation after surgery and are able to discontinue antihypertensive medications completely. The remaining 20–30% have residual essential hypertension that was likely pre-existing or unmasked by the removal of catecholamine-stimulated volume contraction.
• Elimination of catecholamine excess and paroxysms — Complete resection immediately eliminates the source of episodic catecholamine release, resolving the paroxysmal hypertensive crises, diaphoresis attacks, palpitations, and anxiety episodes that dramatically impair quality of life. Most patients report immediate symptomatic relief on recovering from anaesthesia.
• Cardiovascular risk reduction — Chronic catecholamine excess causes catecholamine cardiomyopathy (a reversible takotsubo-like syndrome), left ventricular hypertrophy, and hypertensive end-organ damage. Successful tumour removal allows regression of left ventricular hypertrophy and functional recovery of catecholamine-induced cardiomyopathy, often within 3–6 months.
• Prevention of hypertensive crisis mortality — Undiagnosed phaeochromocytoma carries significant mortality risk during surgical procedures, parturition, endoscopy, or contrast administration. Early diagnosis and surgical cure eliminates this risk. Up to 50% of phaeochromocytoma-related deaths historically occurred in patients whose diagnosis was first established at autopsy.
• Genetic counselling and family screening — Identification of a hereditary mutation (SDH, VHL, RET, NF1) enables targeted surveillance of mutation carriers across the family, allowing early detection of related tumours (medullary thyroid cancer in MEN2, renal cell carcinoma in VHL, CNS haemangioblastoma in VHL) at pre-symptomatic stages when treatment is most effective.
• Glycaemic improvement — Catecholamines suppress insulin secretion and stimulate glycogenolysis, causing secondary diabetes in some patients. Tumour removal normalises glucose metabolism and may resolve catecholamine-induced glucose intolerance.

Pheochromocytoma surgery carries specific anaesthetic and surgical risks that are substantially mitigated by adequate pre-operative preparation and specialist multidisciplinary care:

• Intraoperative hypertensive crisis — Tumour manipulation, particularly during dissection and ligation of the adrenal vein, causes sudden massive catecholamine release and systolic blood pressures exceeding 200–300 mmHg. This risk is substantially reduced (but not eliminated) by adequate pre-operative alpha-blockade and experienced specialist surgical and anaesthetic teams. Intravenous phentolamine or nitroprusside is used for intraoperative blood pressure control.
• Post-resection hypotension — After tumour removal and abrupt cessation of catecholamine production, profound hypotension may occur due to vasodilation of previously catecholamine-contracted vasculature. Managed with aggressive intravenous fluid loading in the 10–14 days pre-operatively (sodium and fluid loading to expand contracted intravascular volume) and post-operatively.
• Post-operative hypoglycaemia — Paradoxical hypoglycaemia after resection is caused by rebound insulin secretion after removal of catecholamine-mediated insulin suppression. Blood glucose monitoring every 2 hours in the first 24 hours post-operatively is mandatory; dextrose infusion may be required.
• Adrenocortical insufficiency — In bilateral adrenalectomy, permanent cortisol and aldosterone deficiency requires lifelong replacement with hydrocortisone and fludrocortisone. Patients must carry an emergency steroid card and self-inject hydrocortisone (sick-day rules) during illness to prevent adrenal crisis. Cortical-sparing surgery reduces but does not eliminate this risk.
• Recurrence and metastatic disease — Even after apparent complete surgical resection, PPGL recurs in 15–17% of patients over 10 years (higher for extra-adrenal and SDHB-mutated tumours). Annual biochemical surveillance is required lifelong. Late metastases may appear 20–30 years after primary resection.
• Surgical complications — General laparoscopic risks include: port-site bleeding, visceral injury (splenic, renal, hepatic), inadvertent injury to the inferior vena cava or aorta (catastrophic but rare), wound infection, venous thromboembolism, and conversion to open surgery in approximately 3–5% of laparoscopic cases.

All patients with pheochromocytoma require lifelong biochemical and imaging surveillance, regardless of the apparent completeness of surgical resection or the histological absence of malignant features:

• Immediate post-operative biochemical testing — Plasma or urine metanephrines should be measured at 2–6 weeks after surgery to confirm complete biochemical cure. Persistently elevated metanephrines indicate residual or metastatic disease. A normal result at 2–6 weeks does not exclude future recurrence.
• Annual biochemical surveillance — The Endocrine Society guidelines recommend annual plasma fractionated metanephrines for a minimum of 10 years in all patients, and lifelong annual testing in those with: hereditary syndromes (MEN2, VHL, SDH mutations), extra-adrenal or multifocal disease, tumour size >5 cm, or young age at diagnosis (<40 years).
• Imaging surveillance — In patients with normal biochemistry, routine cross-sectional imaging is generally not required annually. However, any biochemical recurrence (rising metanephrines) triggers reimaging with CT, MRI, and 68Ga-DOTATATE PET/CT to localise the site of recurrence. SDHB mutation carriers warrant more intensive imaging surveillance given the high malignancy risk.
• Genetic counselling and family cascade testing — All patients with a confirmed germline mutation should be referred to a clinical genetics service. First-degree relatives of mutation carriers should be offered genetic testing and, if positive, tumour surveillance according to syndrome-specific protocols (e.g., annual renal ultrasound and urinary metanephrines for VHL; calcitonin and RET testing for MEN2 relatives).
• Post-operative hydrocortisone management — After unilateral adrenalectomy, the remaining adrenal gland typically compensates adequately. After bilateral adrenalectomy, lifelong glucocorticoid and mineralocorticoid replacement is required. Hydrocortisone sick-day rules and emergency intramuscular hydrocortisone must be provided with written instructions and a steroid alert card.
• Metastatic disease follow-up — Patients with metastatic PPGL receiving 131I-MIBG or PRRT (177Lu-DOTATATE) are reassessed by biochemistry and 68Ga-DOTATATE PET/CT at 3–6 monthly intervals to evaluate response and guide further treatment decisions.

The cost of pheochromocytoma diagnosis and treatment spans biochemical testing, imaging, surgical admission, and lifelong surveillance. Understanding cost drivers helps patients plan and compare treatment options internationally:

• Biochemical diagnostic testing — Plasma fractionated metanephrines are the preferred first-line test. In the UK, NHS laboratory testing is provided without patient charge. Privately, plasma metanephrine panels cost £150–£350. In the US, plasma fractionated metanephrines cost $200–$600 USD without insurance. 24-hour urine catecholamine and metanephrine panels are similarly priced.
• Imaging costs — CT adrenal protocol: £400–£800 (UK private); $800–$1,500 (US). 68Ga-DOTATATE PET/CT: £2,000–£4,000 (UK private); $3,000–$8,000 (US). MRI adrenal: £600–£1,200 (UK private). NHS-funded imaging is provided free at point of care for confirmed or suspected PPGL.
• Surgical admission — Laparoscopic adrenalectomy in a UK NHS trust is provided free of charge. Private surgical fees in the UK range from £8,000–£20,000 including surgeon, anaesthetist, and hospital stay. In India at JCI-accredited centres, laparoscopic adrenalectomy costs approximately $3,000–$6,000 USD — representing 70–85% savings compared to UK private rates.
• Pre-operative medication costs — Phenoxybenzamine (Dibenyline) is the preferred alpha-blocker but can be expensive: approximately £5–£8 per capsule (10 mg), with typical pre-operative courses of 10–14 days at 20–40 mg/day. Doxazosin is a cost-effective alternative at approximately £2–£5 per month.
• Genetic testing costs — Comprehensive germline PPGL gene panel: £400–£1,000 (UK private); NHS-funded when clinical criteria are met. In India and Southeast Asia, panels cost $150–$400 USD.
• MIBG and PRRT therapy — 131I-MIBG (Azedra) therapy in the US costs approximately $400,000–$500,000 USD per treatment course. 177Lu-DOTATATE (Lutathera) costs approximately $45,000 USD per cycle (typically four cycles). These therapies are available through NHS England commissioning for eligible patients in the UK.

Surgical resection is the only curative treatment for localised pheochromocytoma. For patients with inoperable or metastatic disease, several management strategies are available:

• Medical management only (symptom control) — Not curative, but appropriate for patients unfit for surgery or with widespread metastatic disease. Long-term alpha-blockade with phenoxybenzamine or doxazosin controls hypertension and paroxysms. Metyrosine (alpha-methyl-p-tyrosine) — a tyrosine hydroxylase inhibitor that reduces catecholamine synthesis by 40–80% — is an important adjunct for symptom control in inoperable disease, reducing required alpha-blocker doses.
• Percutaneous ablation — Radiofrequency ablation (RFA) or microwave ablation of adrenal tumours has been performed in patients with small recurrent tumours unsuitable for re-operative surgery. Risk of hypertensive crisis during ablation requires the same pre-operative alpha-blockade as surgery. Limited by less complete tumour destruction than surgery.
• Stereotactic body radiotherapy (SBRT) — SBRT delivers precisely targeted high-dose radiation to individual metastatic sites (bone, liver, lymph node). Used for oligometastatic PPGL not amenable to resection or ablation, providing local control rates of 70–90% at 2 years for individual lesions, though not addressing systemic disease.
• Chemotherapy (CVD regimen) — Cyclophosphamide, vincristine, and dacarbazine is the standard cytotoxic regimen for rapidly progressive metastatic PPGL, with response rates of approximately 37% and a median duration of response of 20 months. Generally reserved for patients with high tumour burden, rapidly rising biochemical markers, or progression on radionuclide therapy.
• Targeted molecular therapies — Sunitinib (VEGFR/PDGFR/c-KIT inhibitor) demonstrates activity in phase II studies (clinical benefit rate 63%). Cabozantinib and axitinib are under investigation. Everolimus (mTOR inhibitor) has shown modest activity in SDH-mutated PPGL. These are second-line options for metastatic disease.
• Embolisation — Transcatheter arterial embolisation of hepatic or bone metastases may reduce tumour mass and catecholamine output, providing palliative symptom control and enabling dose reduction of alpha-blockers in selected patients with high hepatic tumour burden.